Galectin Therapeutics Inc. (GALT)

[thefamilyman]

I understand that I am apparently in the minority with my opinion of Traber, at least on this forum. I don't think he's an asset. I think he's a liability who will be a continuing drag our stock price as long as he remains our CEO. One thing's for sure, his decision making has resulted in a tremendous "buying opportunity" for Traber and his friends. I can't help but wonder if that was what he intended when he surprised us with the change in protocol for Cohort 2. I also can't help but wonder if HE'S surprised by how long the effects of his deception are lingering?

Perhaps if the share price is still in the $3 to $5 range later this summer, the BOD will wake up and take action...

Genfit announced tepid results which is benefiting ICPT stock price. I believe it would have run GALT as well if it wasn't for the shares being sold to raise capital. Can't wait for them to stop the issuing of new shares.

I don't agree with familyman in his critisizm of Traber. He's a huge asset to the company and the only important task for the company to succeed is to successfully design the Phase 2 to get the drug to market. - jmh0602